Cargando…

Interleukin-5 in the Pathophysiology of Severe Asthma

Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival, and degranulation of eosinophils. Indeed, during the last years, significant advances have been made in our understanding of the cellular and molecular mechanisms underlying the powerful actions of IL-5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelaia, Corrado, Paoletti, Giovanni, Puggioni, Francesca, Racca, Francesca, Pelaia, Girolamo, Canonica, Giorgio Walter, Heffler, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927944/ https://www.ncbi.nlm.nih.gov/pubmed/31920718 http://dx.doi.org/10.3389/fphys.2019.01514

Ejemplares similares

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
por: Pelaia, Corrado, et al.
Publicado: (2022)

Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets
por: Racca, Francesca, et al.
Publicado: (2022)

Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model
por: Malipiero, Giacomo, et al.
Publicado: (2020)

Mast Cells in Upper and Lower Airway Diseases: Sentinels in the Front Line
por: Costanzo, Giovanni, et al.
Publicado: (2023)

A critical appraisal on AIT in childhood asthma
por: Ferrando, Matteo, et al.
Publicado: (2018)

New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
por: Nappi, Emanuele, et al.
Publicado: (2022)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI
por: Senna, Gianenrico, et al.
Publicado: (2020)

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
por: Bagnasco, Diego, et al.
Publicado: (2017)

Targeted therapy in severe asthma today: focus on immunoglobulin E
por: Pelaia, Girolamo, et al.
Publicado: (2017)

Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
por: Puggioni, Francesca, et al.
Publicado: (2020)

Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic
por: Patella, Vincenzo, et al.
Publicado: (2022)

Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

An academic allergy unit during COVID-19 pandemic in Italy
por: Malipiero, Giacomo, et al.
Publicado: (2020)

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
por: Canonica, Giorgio Walter, et al.
Publicado: (2019)

Desensitization Protocols for Anti-SARS-CoV-2 Vaccines in Patients with High Risk of Allergic Reactions
por: Messina, Maria Rita, et al.
Publicado: (2023)

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022)

Extended IgE profile based on an allergen macroarray: a novel tool for precision medicine in allergy diagnosis
por: Heffler, Enrico, et al.
Publicado: (2018)

Personalized Approach to Severe Asthma
por: Heffler, Enrico, et al.
Publicado: (2018)

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
por: Pelaia, Corrado, et al.
Publicado: (2018)

Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps
por: Baiardini, Ilaria, et al.
Publicado: (2022)

Immunostimulants in respiratory diseases: focus on Pidotimod
por: Puggioni, Francesca, et al.
Publicado: (2019)

Polyethylene Glycol and Polysorbate 80 Skin Tests in the Context of an Allergic Risk Assessment for Hypersensitivity Reactions to Anti-SARS-CoV-2 mRNA Vaccines
por: Nappi, Emanuele, et al.
Publicado: (2023)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital()
por: Paoletti, Giovanni, et al.
Publicado: (2021)

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
por: Pelaia, Corrado, et al.
Publicado: (2018)

Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma
por: Lombardo, Nicola, et al.
Publicado: (2020)

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
por: Vatrella, Alessandro, et al.
Publicado: (2022)

The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital
por: Paoletti, Giovanni, et al.
Publicado: (2023)

Special Issue on ‘Asthma and Allergic Inflammation’
por: Pelaia, Corrado
Publicado: (2023)

Biologics in severe asthma: the role of real-world evidence from registries
por: Paoletti, Giovanni, et al.
Publicado: (2022)

The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
por: Marone, Giancarlo, et al.
Publicado: (2019)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Biologics and airway remodeling in severe asthma
por: Varricchi, Gilda, et al.
Publicado: (2022)

Novel Biological Therapies for Severe Asthma Endotypes
por: Pelaia, Corrado, et al.
Publicado: (2022)

Oral Corticosteroid Abuse and Self-Prescription in Italy: A Perspective from Community Pharmacists and Sales Reports before and during the COVID-19 Era
por: Nappi, Emanuele, et al.
Publicado: (2023)

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies
por: Pelaia, Corrado, et al.
Publicado: (2021)

Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis
por: Heffler, Enrico, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ejc4o02kfra7h5hge9jdeni5dr